Evidence map›Paper›PMID 25071098›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2014

18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium.

Katherine Zukotynski, Frederic Fahey, Mehmet Kocak, Larry Kun, James Boyett, Maryam Fouladi, Sridhar Vajapeyam, Ted Treves, Tina Y Poussaint

Open access · bronzeAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Article
  8. The British journal of radiology · 2019
    Review
  9. CouldEuropean journal of nuclear medicine and molecular imaging · 2018
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Katherine ZukotynskiDepartment of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada Department of Radiology, Harvard Medical School, Boston, Massachusetts.
Frederic FaheyDepartment of Radiology, Harvard Medical School, Boston, Massachusetts Department of Radiology, Boston Children's Hospital, Boston, Massachusetts.
Mehmet KocakDepartment of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
Larry KunDepartment of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
James BoyettDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee; and.
Maryam FouladiDepartment of Hematology/Oncology, Cincinnati Children's Medical Center, Cincinnati, Ohio.
Sridhar VajapeyamDepartment of Radiology, Harvard Medical School, Boston, Massachusetts Department of Radiology, Boston Children's Hospital, Boston, Massachusetts.
Ted TrevesDepartment of Radiology, Harvard Medical School, Boston, Massachusetts Department of Radiology, Boston Children's Hospital, Boston, Massachusetts.
Tina Y PoussaintDepartment of Radiology, Harvard Medical School, Boston, Massachusetts Department of Radiology, Boston Children's Hospital, Boston, Massachusetts tinayoung.poussaint@childrens.harvard.edu.
Harvard University · USSt. Jude Children's Research Hospital · USBoston Children's Hospital · USCincinnati Children's Hospital Medical Center · USSunnybrook Health Science Centre · CAUniversity of Tennessee Health Science Center · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Pediatric Brain Tumor Consortium (PBTC)UM1CA081457 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Ira J Dunkel, Arzu Onar-Thomas · 2014 to 2026
$41.4M
The Pediatric Brain Tumor Consortium (PBTC)U01CA081457 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BOYETT, JAMES MILFORD · 1999 to 2013
$29.2M
NCI NIH HHS P30 CA021765NCI NIH HHS U01 CA081457NCI NIH HHS U01 CA81457NCI NIH HHS UM1 CA081457
6 · The paper itself

Abstract

unlabelledThe purpose of this study was to describe (18)F-FDG uptake across a spectrum of pediatric brain tumors and correlate (18)F-FDG PET with MR imaging variables, progression-free survival (PFS), and overall survival (OS).

methodsA retrospective analysis was conducted of children enrolled in phase I/II clinical trials through the Pediatric Brain Tumor Consortium from August 2000 to June 2010. PET variables were summarized within diagnostic categories using descriptive statistics. Associations of PET with MR imaging variables and PFS and OS by tumor types were evaluated.

resultsBaseline (18)F-FDG PET was available in 203 children; 66 had newly diagnosed brain tumors, and 137 had recurrent/refractory brain tumors before enrolling in a Pediatric Brain Tumor Consortium trial. MR imaging was performed within 2 wk of PET and before therapy in all cases. The (18)F-FDG uptake pattern and MR imaging contrast enhancement (CE) varied by tumor type. On average, glioblastoma multiforme and medulloblastoma had uniform, intense uptake throughout the tumor, whereas brain stem gliomas (BSGs) had low uptake in less than 50% of the tumor and ependymoma had low uptake throughout the tumor. For newly diagnosed BSG, correlation of (18)F-FDG uptake with CE portended reduced OS (P = 0.032); in refractory/recurrent BSG, lack of correlation between (18)F-FDG uptake and CE suggested decreased PFS (P = 0.023). In newly diagnosed BSG for which more than 50% of the tumor had (18)F-FDG uptake, there was a suggestion of lower apparent diffusion coefficient (P = 0.061) and decreased PFS (P = 0.065).

conclusion(18)F-FDG PET and MR imaging showed a spectrum of patterns depending on tumor type. In newly diagnosed BSG, the correlation of (18)F-FDG uptake and CE suggested decreased OS, likely related to more aggressive disease. When more than 50% of the tumor had (18)F-FDG uptake, the apparent diffusion coefficient was lower, consistent with increased cellularity. In refractory/recurrent BSG, poor correlation between (18)F-FDG uptake and CE was associated with decreased PFS, which may reflect concurrent tissue breakdown at sites of treated disease and development of new sites of (18)F-FDG-avid malignancy.

Indexed as

Fluorodeoxyglucose F18RadiopharmaceuticalsAdolescentAdultBrain NeoplasmsChildChild, PreschoolFemaleGliomaHumansInfantMagnetic Resonance ImagingMalePositron-Emission TomographyRetrospective StudiesFluorodeoxyglucose F18Radiopharmaceuticals18F-FDG PETbrain tumorMR diffusionpediatric

Identifiers

PMID25071098
PMCPMC4249729
OpenAlexW2032880673

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.